MedTrace Logo

Thymoglobulin Induction in Kidney Transplant Recipients

NCT01239563 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-11-11

No results posted yet for this study

Summary

The purpose of this study is to determine if anti-thymocyte globulin (Thymoglobuline) administration in the kidney transplant recipient is able to reduce the amount of damage that kidneys transplanted from deceased donors sustains on reperfusion.

Conditions

  • Kidney Transplantation
  • Ischemia-Reperfusion Injury

Interventions

DRUG

antithymocyte globulin

Thymoglobulin 1.5mg/kg, 4 doses Thymoglobulin 6mg/kg, single dose

DRUG

Basiliximab

Intravenous 20mg, day 0\&4

Sponsors & Collaborators

  • Oxford University Hospitals NHS Trust

    collaborator OTHER

  • Genzyme, a Sanofi Company

    collaborator INDUSTRY

  • University of Oxford

    lead OTHER

Principal Investigators

  • Peter J Friend, MD FRCS · University of Oxford

  • Susan V Fuggle, DPhil MRCPath · Oxford Radclifffe Hospitals NHS Trust

  • Kathryn Wood, DPhil BSc · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-05-31
Completion
2016-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01239563 on ClinicalTrials.gov